Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05765500 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

StatusRecruiting
PhasePhase 2
Started2024-02-12
View on ClinicalTrials.gov ↗

Amendment history

2026-07-29
Study Status, Sponsor/Collaborators v5
Collaborators3 entries, revised
MyovantSumitomo SciencesPharma GmbHAmerica, Inc.
2025-08-05
Study Status v4
Primary completion date2025-07-01→2027-07-01
Completion date2026-01-01→2028-01-01
2025-04-10
Study Status v3
Re-verified, no change to tracked fields
2024-02-13
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-01→confirmed 2024-02-12
Study sitesdetails revised at 3 of 3 sites
2023-12-18
Study Status v1
Start date2023-08→2024-01
2023-03-01
Original filing
This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label. The names of the study drugs involved in this study are: * Leuprolide (type of ADT) * Relugolix (type of ADT)
Trial Details
NCT Number NCT05765500
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Prostate Cancer Foundation, Pfizer, Sumitomo Pharma America, Inc.
Conditions Prostate Cancer, Prostatic Neoplasms
Enrollment 110 participants
Start Date 2024-02-12
Primary Completion 2027-07-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-30